Laboratory measurement of the direct oral anticoagulants

British Journal of Haematology

Volumn 172, Issue 3, 2016, Pages 315-336

  Dale, Brian J ^a   Chan, Noel C ^b   Eikelboom, John W ^b,c,d  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulants; Coagulation; Drugs; Laboratory haematology; Thrombosis

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT; DABIGATRAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ACTIVATED CLOTTING TIME; BLOOD CLOTTING PARAMETERS; BLOOD EXAMINATION; DILUTE RUSSELL VIPER VENOM TIME; DILUTE THROMBIN TIME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; ECARIN CHROMOGENIC ASSAY; ECARIN CLOT TIME; HEMOSTASIS TEST; HUMAN; LABORATORY TEST; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTHROMBINASE INDUCED CLOT TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTATIONAL THROMBOELASTOGRAPHY; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DABIGATRAN; DRUG MONITORING; HUMANS; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; THIAZOLES;

EID: 84955733026     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13810     Document Type: Review

References (93)

1. Adcock, D.M. & Gosselin, R. (2015) Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thrombosis Research, 136, 7-12.
2. Adelmann, D., Wiegele, M., Wohlgemuth, R.K., Koch, S., Frantal, S., Qiehenberger, P., Scharbert, G., Kozek-Langenecker, S. & Schaden, E. (2014) Measuring the activity of apixaban and rivaroxaban with rotational thromboelastometry. Thrombosis Research, 134, 918-923.
3. Asmis, L.M., Alberio, L., Angelillo-Scherrer, A., Korte, W., Reber, G., Seifert, B., Stricker, H., Tsakiris, D.A. & Wuillemin, W.A. (2012) Rivaroxaban quantification by anti-FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thrombosis Research, 129, 492-498.
4. Baglin, T. (2005) The measurement and application of thrombin generation. British Journal of Haematology, 130, 653-661.
5. Baglin, T., Keeling, D. & Kitchen, S. (2012) Effects of routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the british committee for standards in haematology. British Journal of Haematology, 159, 427-429.
6. Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H. & Ageno, W. (2013) Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 11, 756-760.
7. Barrett, Y.C., Wang, Z., Frost, C. & Shenker, A. (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thrombosis and Haemostasis, 104, 1263-1271.
8. Barrett, Y.C., Wang, Z. & Knabb, R.M. (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clinical and Applied Thrombosis/Hemostasis, 19, 522-528.
9. Bathala, M.S., Masumoto, H., Oguma, T., He, L., Lowrie, C. & Mendell, J. (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metabolism and Disposition, 40, 2250-2255.
10. Becker, R.C., Yang, H., Barrett, Y., Mohan, P., Wang, J., Wallentin, L. & Alexander, J.H. (2011) Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. Journal of Thrombosis and Thrombolysis, 32, 183-187.
11. Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition, 36, 386-399.
12. Brummel, K.E., Paradis, S.G., Butenas, S. & Mann, K.G. (2002) Thrombin functions during tissue-factor induced blood coagulation. Blood, 100, 148-152.
13. Calatzis, A., Preetz, D., Haas, S., Spannagl, M., Rudin, K. & Wilmer, M. (2008) Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. American Journal of Clinical Pathology, 130, 446-454.
14. Cuker, A. & Husseinzadeh, H. (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. Journal of Thrombosis and Thrombolysis, 39, 288-294.
15. Cuker, A., Siegal, D.M., Crowther, M.A. & Garcia, D.A. (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. Journal of the American College of Cardiology, 64, 1128-1139.
16. Dager, W.E., Gosselin, R.C., Kitchen, S. & Dwyre, D. (2012) Dabigatran effects on the international normalized ration, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicentre, in vitro study. Annals of Pharmacotherapy, 46, 1627-1635.
17. Dale, B., Eikelboom, J.W., Weitz, J.I., Young, E., Paikin, J.S., Coppens, M., Whitlock, R.P., Connolly, S.J., Ginsberg, J.S. & Hirsh, J. (2013) Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial haemorrhage and myocardial infarction? Journal of Thrombosis and Thrombolysis, 35, 295-301.
18. Dale, B.J., Ginsberg, J.S., Johnston, M., Hirsh, J., Weitz, J.I. & Eikelboom, J.W. (2014) Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. Journal of Thrombosis and Haemostasis, 12, 1810-1815.
19. Davis, P.K., Musunuru, H., Walsh, M., Mitra, R., Ploplis, V. & Castellino, F.J. (2012) The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Thrombosis and Haemostasis, 108, 586-588.
20. Delavenne, X., Mismetti, P. & Bassett, T. (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 78-79, 150-153.
21. Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B. & Dogne, J.-M. (2012a) Impact of dabigatran on a large panel of routine or specific coagulation assays. Thrombosis and Haemostasis, 107, 985-997.
22. Douxfils, J., Mullier, F., Loosen, C. & Chatelain, C. (2012b) Assessment of the impact of rivaroxaban on routine and specific coagulation assays: a practical laboratory guide. Thrombosis and Haemostasis, 130, 956-966.
23. Douxfils, J., Dogne, J.-M., Mullier, F., Chatelain, B., Ronquist-Nii, Y., Malmstrom, R.E. & Hjemdahl, P. (2013a) Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and Haemostasis, 110, 543-549.
24. Douxfils, J., Tamigniau, A., Chatelain, B., Chatelain, C., Wallemacq, P., Mullier, F. & Donge, J.-M. (2013b) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thrombosis and Haemostasis, 110, 723-731.
25. Douxfils, J., Chatelain, C., Chatelain, B., Dogne, J.-M. & Mullier, F. (2013c) Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thrombosis and Haemostasis, 110, 283-294.
26. Douxfils, J., Lessire, S., Dincq, A.S., Hjemdahl, P., Ronquist-Nii, Y., Pohanka, A., Gourdin, M., Chatelain, B., Dogne, J.M. & Mullier, F. (2015a) Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thrombosis and Haemostasis, 113, 862-869.
27. Douxfils, J., Chatelain, B., Hjemdahl, P., Devalet, B., Sennesael, A.-L., Wallemacq, P., Ronquist-Nii, Y., Pohanka, A., Dogne, J.-M. & Mullier, F. (2015b) Does the Russell viper venom time provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thrombosis Research, 135, 852-860.
28. Du, S., Kramer, S., Giese, C., Weiss, C., Wehling, M., Wehling, M., Kramer, R. & Harenberg, J. (2015) Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples. Thrombosis and Haemostasis, 113, 1149-1151.
29. Escolar, G., Arellano-Rodrigo, E., Lopez-Vilchez, I., Molina, P., Sanchis, J., Reverter, J.C., Carne, X., Cid, J., Villalta, J., Tassies, D., Galan, A.M. & Diaz-Ricart, M. (2015) Reversal of rivaroxaban-induced alteration on hemostasis by different coagulation factor concentrates. Circulation Journal, 79, 331-338.
30. Exner, T., Ellwood, L., Rubie, J. & Barancewicz, A. (2013) Testing for new oral anticoagulants with LA resistant Russells viper venom reagents. An in vitro study. Thrombosis and Haemostasis, 109, 762-765.
31. Freyburger, G., Macouillard, G., Labrouche, S. & Sztark, F. (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thrombosis Research, 127, 457-465.
32. Furugohri, T., Isobe, K., Honda, Y., Kamisato-Matsumoto, C., Sugiyama, N., Nagahara, T., Morishima, Y. & Shibano, T. (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. Journal of Thrombosis and Haemostasis, 6, 1542-1549.
33. Gerotziafas, G.T., Elalamy, I., Depasse, F., Perzborn, E. & Samama, M.M. (2007) In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. Journal of Thrombosis and Haemostasis, 5, 886-888.
34. Gosselin, R., Hawes, E., Moll, S. & Adcock, D. (2014a) Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses. American Journal of Clinical Pathology, 141, 262-267.
35. Gosselin, R.C., Funk, D.M., Taylor, J.M., Francart, S.J., Hawes, E., Friedman, K.D. & Moll, S. (2014b) Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Archives of Pathology and Laboratory Medicine, 138, 1680-1684.
36. Gouin-Thibault, I., Flaujac, C., Delavenne, X., Quenet, S., Horellou, M.-H., Laporte, S., Siguret, V. & Lecompte, T. (2014) Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. Thrombosis and Haemostasis, 111, 240-248.
37. Gous, T., Couchman, L., Patel, J.P., Paradzai, C., Arya, R. & Flanagan, R.J. (2014) Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Therapeutic Drug Monitoring, 36, 597-605.
38. Hapgood, G., Butler, J., Malan, E., Chunilal, S. & Tran, H. (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient samples. Thrombosis and Haemostasis, 110, 308-315.
39. Harenberg, J., Giese, C., Marx, S. & Kramer, R. (2012) Determination of dabigatran in human plasma samples. Seminars in Thrombosis and Hemostasis, 38, 16-22.
40. Hawes, E.M., Deal, A.M., Funk-Adcock, D., Gosselin, R., Jeanneret, C., Cook, A.M., Taylor, J.M., Whinna, H.C., Winkler, A.M. & Moll, S. (2013) Performance of coagulation tests on therapeutic doses of dabigatran: a cross-sectional pharmacodynamics study based on peak and trough levels. Journal of Thrombosis and Haemostasis, 11, 1493-1502.
41. He, S., Wallen, H., Bark, N. & Blomback, M. (2013) In vitro studies using a global hemostasis assay to examine anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. Journal of Thrombosis and Thrombolysis, 35, 131-139.
42. Hemker, H.C., Willems, G.M. & Beguin, S. (1986) A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thrombosis and Haemostasis, 56, 9-17.
43. Herrmann, R., Thom, J., Wood, A., Phillips, M., Muhammad, S. & Baker, R. (2014) Thrombin generation using the calibrated automated Thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thrombosis and Haemostasis, 111, 989-995.
44. Hillarp, A., Baghaei, F., Blixter, F.I., Gustarfsson, K.M., Stigebdal, L., Sten-Linder, M., Stradberg, K. & Lindhal, T.L. (2010) Effect of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. Journal of Thrombosis and Haemostasis, 9, 133-139.
45. Hillarp, A., Gustafsson, K.M., Faxalav, L., Strandberg, K., Baghaei, F., Blixter, I.F., Berndtsson, M. & Lindahl, T.L. (2014) Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays. Journal of Thrombosis and Haemostasis, 12, 1545-1553.
46. Iqbal, M., Khalil, N.Y., Imam, F. & Anwer, K. (2015) A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. Journal of Thrombosis and Thrombolysis, 39, 79-88.
47. Kitchen, S., Theaker, J. & Preston, F.E. (2000) Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagulation and Fibrinolysis, 11, 137-144.
48. Kyriakou, E., Ikonomidis, I., Stylos, D., Bonovas, S., Papadakis, I., Nikolopoulos, G., Kokoris, S., Kalantzis, D., Economopoulou, C., Kopterides, P., Lekakis, J. & Tsantes, E. (2015) Laboratory assessment of the anticoagulant activity of dabigatran. Clinical and Applied Thrombosis/Hemostasis, 21, 434-445.
49. Laux, V., Perzborn, E., Kubitza, D. & Misselwitz, F. (2007) Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Seminars in Thrombosis and Hemostasis, 33, 515-523.
50. Lind, S.E., Boyle, M.E., Fisher, S., Ishimoto, J., Trujillo, T.C. & Kiser, T.H. (2014) Comparison of the aPTT with alternative tests of monitoring direct thrombin inhibitors in patient samples. American Journal of Clinical Pathology, 141, 665-674.
51. Lindahl, T.L., Baghaei, F., Blixter, I.F., Gustafsson, K.M., Stigendal, L., Sten-Linder, M., Strandberg, K. & Hillarp, A. (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thrombosis and Haemostasis, 105, 371-378.
52. Loeffen, R., Kleinegris, M.C., Loubele, S.T., Pluijmen, P.H., Fens, D., van Oerle, R., Ten Cate, H. & Spronk, H.M.K. (2012) Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. Journal of Thrombosis and Haemostasis, 10, 2544-2554.
53. Macfarlane, R.G. & Biggs, R. (1953) A thrombin generation test: the application in haemophilia and thrombocytopenia. Journal of Clinical Pathology, 6, 3-8.
54. Mani, H., Rohnde, G., Stratmann, G., Hesse, C., Herth, N., Schwers, S. & Lindhoff-Last, E. (2012) Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of Antithrombin. Thrombosis and Haemostasis, 108, 191-198.
55. Martin, A.C., Gouin-Thibault, I., Siguret, V., Mordohay, A., Samama, C.M., Gaussem, P., Le Bonniec, B. & Godier, A. (2015) Multimodal assessment of non-specific hemostatic agents for apixaban reversal. Journal of Thrombosis and Haemostasis, 13, 426-436.
56. McGlasson, D.L., Kaczor, D.A., Krasuski, R.A., Campbell, C.L., Kostur, M.R. & Adinaro, J.T. (2005) Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagulation and Fibrinolysis, 16, 173-176.
57. Mendell, J., Tachibana, M., Shi, M. & Kunitada, S. (2011) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. Journal of Clinical Pharmacology, 51, 687-694.
58. Mendell, J., Noveck, R.J. & Shi, M. (2012) A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. British Journal of Clinical Pharmacology, 75, 966-978.
59. Molenaar, P.J., Dinkelaar, J. & Leyte, A. (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clinical Chemistry and Laboratory Medicine, 50, 1799-1807.
60. Morishima, Y. & Kamisato, C. (2015) Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. American Journal of Clinical Pathology, 143, 241-247.
61. Mueck, W., Eriksson, B.I., Bauer, K., Borris, L., Dahl, O.E., Fisher, W.D., Gent, M., Haas, S., Huismann, M.V., Kakkar, A.K., Kalebo, P., Kwong, L.M., Misselwitz, F. & Turpie, A.G. (2008) Population pharmacokinetics and Pharmacodynamics of Rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clinical Pharmacokinetics, 47, 203-216.
62. Mueck, W., Lensing, A.W.A., Agnelli, G., Decousus, H., Prandoni, P. & Misselwitz, F. (2011) Population pharmacokinetic analyses in patients treated for acute deep vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clinical Pharmacokinetics, 50, 675-686.
63. Nakano, Y., Kondo, T., Osanai, H., Murase, Y., Nakashima, Y., Asano, H., Ajioka, M., Sakai, K., Inden, Y. & Murohara, T. (2015) Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. Journal of Cardiology, 65, 185-190.
64. Nowak, G. (2003) The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiology of Haemostasis and Thrombosis, 33, 173-183.
65. Ogata, K., Mendell-Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M. & Kunitada, S. (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. Journal of Clinical Pharmacology, 50, 743-753.
66. Patel, J.P., Chitongo, P.B., Czuprynska, J., Roberts, L.N., Patel, R.K. & Arya, R. (2015) Normal prothrombin times in the presence of therapeutic levels of apixaban - in vivo experience from King's College Hospital. British Journal of Haematology, 169, 152-153.
67. Perzborn, E., Strassburger, J., Wilmen, A., Pohlmann, J., Roehrig, S., Schlemmer, K.-H. & Straub, A. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. Journal of Thrombosis and Haemostasis, 3, 514-512.
68. Raghavan, N., Frost, C.E., Yu, Z.S., He, K., Zhang, H., Humphreys, W.G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P.C. & Zhang, D. (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metabolism and Disposition, 37, 74-81.
69. Rathbun, S., Tafur, A., Grant, R., Esmon, N., Mauer, K. & Marlar, R. (2015) Comparison of methods to determine rivaroxaban anti-factor-Xa activity. Thrombosis Research, 135, 394-397.
70. Reilly, P.A., Lehr, T., Haertter, S., Connolly, S.J., Yusuf, S., Eikelboom, J.W., Ezekowitz, M.D., Nehmiz, G., Wang, S. & Wallentin, L. (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ishemic stroke and major bleeding in atrial fibrillation patients. Journal of the American College of Cardiology, 63, 321-328.
71. Rodgers, S.E., Wong, A., Gopal, R.D., Dale, B.J., Duncan, E.M. & McRae, S.J. (2014) Evaluation of pre-analytical variables in a commercial thrombin generation assay. Thrombosis Research, 134, 160-164.
72. Samama, M.M., Martinoli, J.-L., Le Flem, L., Guiet, C., Plu-Bureau, B., Depasse, F. & Perzborn, E. (2010) Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis, 103, 815-825.
73. Samama, M.M., Contant, G., Spiro, T.E., Perzborn, E., Le Flem, L., Guinet, C., Gourmelin, Y. & Martinoli, J.L. (2012a) Evaluation of the prothrombin time for measuring rivaroxaban concentrations using calibrators and controls: results of a multicentre field trial. Clinical and Applied Thrombosis and Hemostasis, 18, 150-158.
74. Samama, M.M., Mendell, J., Guinet, C., Le Flem, L. & Kunitada, S. (2012b) In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thrombosis Research, 129, e77-e82.
75. Samama, M.M., Guinet, C., Le Flem, L., Ninin, E. & Debue, J.-M. (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopaedic surgery: an observational study. Journal of Thrombosis and Thrombolysis, 35, 140-146.
76. Schmitz, E.M.H., Boonen, K., Van Den Heuvel, D.J.A., Van Dongen, J.L.J., Schellings, M.W.M., Emmen, J.M.A., Van Der Graff, F., Brunsveld, L. & Van De Kerkhof, D. (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. Journal of Thrombosis and Haemostasis, 12, 1636-1646.
77. Stangier, J. (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetics, 47, 285-295.
78. Stangier, J. & Feuring, M. (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagulation and Fibrinolysis, 23, 138-143.
79. Stangier, J., Rathgen, K., Stahle, H., Gansser, D. & Roth, W. (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British Journal of Clinical Pharmacology, 64, 292-303.
80. Stangier, J., Stahle, H., Rathgen, K. & Fuhr, R. (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clinical Pharmacokinetics, 47, 47-59.
81. Summary of Product Characteristics, Electronic Medicines Compendium (United Kingdom and Europe). (2014) http://www.medicines.org.uk/emc/medicine/27220#PHARMACODYNAMIC_PROPS. Accessed 17 August 2015.
82. Tripodi, A., Chantarangkul, V., Guinet, C. & Samama, M.M. (2011) The international normalized ratio for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. Journal of Thrombosis and Haemostasis, 9, 226-228.
83. Van Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M. & Clemens, A. (2010) Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis, 103, 1116-1127.
84. Van Veen, J.J., Gatt, A. & Makris, M. (2008) Thrombin generation testing in routine clinical practice: are we there yet? British Journal of Haematology, 142, 889-903.
85. Wang, L., Raghavan, N., He, K., Luettgen, J.M., Humphreys, W.G., Knabb, R.M., Pinto, D.J. & Zhang, D. (2009) Sulfation of O-demethyl apixaban: enzyme identification and species comparison. Drug Metabolism and Disposition, 37, 802-808.
86. Weinz, C., Schwarz, T., Kubitza, D., Mueck, W. & Lang, D. (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metabolism and Disposition, 37, 1056-1064.
87. Weitz, J.I., Connolly, S.J., Patel, I., Salazar, D., Rohatagi, S., Mendell, J., Kastrissios, H., Jin, J. & Kunitada, S. (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis, 104, 633-641.
88. Wienen, W., Stassen, J.M., Priepke, H., Ries, U.J. & Hauel, N. (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thrombosis and Haemostasis, 98, 155-162.
89. Wong, P.C., Crain, E.J., Xin, B., Wexler, R.R., Lam, P.Y.S., Pinto, D.J., Luettgen, J.M. & Knabb, R.M. (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis, 6, 820-829.
90. Wong, P.C., Pinto, D.J.P. & Zhang, D. (2011) Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. Journal of Thrombosis and Thrombolysis, 31, 478-492.
91. Wong, P.C., White, A. & Luettgen, J. (2013) Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. Hospital Practice, 41, 19-25.
92. Xu, Y., Wu, W., Wang, L., Chintala, M., Plump, A.S., Ogletree, M.L. & Chen, Z. (2013) Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigratran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagulation and Fibrinolysis, 24, 332-338.
93. 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metabolism and Disposition, 37, 1738-1748.